drugset / Trial / NCT03688022

Relative Bioavailability and Drug-drug Interaction Study With MT-7117 and a Proton Pump Inhibitor

NCT03688022 ↗

Phase 1 Completed 50 enrolled Tanabe Pharma America, Inc.
RandomizedCrossoverOpen-labelOther

Summary

An open label, multicentre, randomised, 2-cohort, sequential and crossover study to assess the relative oral bioavailability of MT-7117 higher content tablets versus MT-7117 lower content tablets and the pharmacokinetics of MT-7117 under various gastric conditions (fed and fasted, and following administration of a proton pump inhibitor and an acidic beverage) in healthy subjects

Timeline

Start
2018-10-25
Primary completion
2018-12-22
Completion
2018-12-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Dersimelagon Small molecule — Oral

Indications

No indication recorded.